Innovations in Oligonucleotide Manufacturing
Eurofins Genomics US has recently taken a major step forward in its manufacturing capabilities by opening a cutting-edge oligonucleotide facility. This expansion comes in direct response to the growing need for high-quality GMP-grade and research-use oligonucleotides.
Facility Overview and Capabilities
The newly established GMP facility features a modern design that prioritizes strict quality control. Eurofins Genomics US now has entirely separate production lines for Research Use Only (RUO) and Good Manufacturing Practice (GMP) products. This thorough approach enhances its offerings in both molecular diagnostics and therapeutic applications, ensuring each oligonucleotide product meets the highest standards for quality and safety.
Commitment to Quality
Sumit Gupta, the president of Eurofins Genomics US, shared his pride in this milestone, saying, "This marks a significant commitment to excellence and innovation in genomics." His remarks underscore the company's dedication to continuous improvement and ensuring quality.
Technological Advancements
Spanning over 75,000 square feet, the facility includes advanced automation and precision process controls. These technological advancements are essential for boosting production efficiency and maintaining the purity of synthetic DNA and RNA. This is especially important for next-generation sequencing (NGS) applications, where high-quality oligonucleotides are critical.
Investment in Future Growth
This recent expansion also includes substantial investments in new equipment that is expected to nearly double production capacity. As Eurofins Genomics US enhances its manufacturing capabilities, the company aims to maintain consistent quality and shorten lead times, positioning itself as a leader in satisfying the rising demands of regulated industries.
Company Insights
Eurofins Scientific, the parent company, is recognized worldwide as a leader in various testing domains, including food, environmental, pharmaceutical, and cosmetics product testing. With a vast network of over 62,000 employees and more than 900 independent companies operating in 62 countries, Eurofins offers a comprehensive portfolio of analytical methods to guarantee the purity and safety of biological substances. This extensive expertise strengthens the company's ability to deliver top-quality oligonucleotide products.
As Eurofins Genomics US progresses, the new facility exemplifies its steadfast commitment to innovation and quality in the fast-evolving field of genomics.
Frequently Asked Questions
What is the significance of the new facility for Eurofins Genomics US?
The new facility boosts manufacturing capacity and enhances quality assurance for GMP-grade and research-use oligonucleotides, meeting global demands.
How does segregation in the production process benefit quality control?
Segregated production lines ensure that various products are created under strictly controlled conditions, adhering to essential quality standards.
What types of applications will benefit from the new manufacturing capabilities?
This facility is designed to support molecular diagnostics, therapeutics, and clinical applications, particularly in NGS sequencing.
What are the future goals for Eurofins Genomics US?
The aim is to consistently enhance product quality, cut lead times, and expand capacity to keep up with increasing industry demands.
How does Eurofins Scientific support its subsidiary’s advancements?
Eurofins Scientific offers comprehensive resources and expertise through its global network, ensuring that innovations and quality standards are maintained at all levels.
